George Sledge responds to Berry’s letter: Neoadjuvant doesn’t predict adjuvant in breast cancer and Berry’s rejoinder

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As always, I both enjoyed and learned something interesting from Dr. Don Berry, one of the great biostatisticians of our era. I find, reading his analysis of ALTTO and NeoALTTO, much that I agree with. I am certainly no statistician, and must bow to his statistical analysis of ALTTO and NeoALTTO. And yet at the same time I think it misses the point. So I will beg to differ.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
George W. Sledge Jr.
Chief of oncology, Stanford University
Donald A. Berry
Professor of biostatistics, MD Anderson Cancer Center

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
George W. Sledge Jr.
Chief of oncology, Stanford University
Donald A. Berry
Professor of biostatistics, MD Anderson Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login